Hematology Xagena

Xagena Mappa
Xagena Newsletter
Medical Meeting

Search results for "Ruxolitinib"

The results of phase III study evaluating a JAK 1/2 inhibitor for the treatment of polycythemia vera were presented at the 50th Annual Meeting of the American Society of Clinical Oncology ( ASCO ). ...

Data from the largest clinical trial of myelofibrosis patients treated with Ruxolitinib ( Jakavi ) were presented at 56th Annual Meeting of the American Society of Hematology ( ASH ) in San Francisco ...

There are considerable advances in the understanding of the Philadelphia-chromosome (Ph)-negative myeloproliferative neoplasms ( MPN ) in the past 10 years including unraveling the mutation topography ...